Phase 2 N=180 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=279 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Phase 3 N=236 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Phase 2 N=76 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Phase 2 N=20 Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants
Phase 2 N=21 Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
Phase 2 N=50 Pediatric GVHD Low Risk Steroid Taper Trial
Acute Graft vs Host Disease · Allogeneic Bone Marrow Transplantation · Adverse Effects
Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants
Phase 3 N=164 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
Graft Versus Host Disease · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08
Phase 2 N=60 Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Graft vs Host Disease
Primary: Cummalative Incidence of Grade 2 to 4 Acute Graft vs Host Diesease (GVHD) at Day 100 Post Transplant in HSCT Recipients — 3.3 percentage of participants — p=<0.05
Phase 2 N=30 A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
Graft-versus-host-disease · GVHD
Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants
Phase 2 N=22 Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
Graft-Versus-Host Disease
Primary: Phase I: Maximum Tolerated Dose (MTD) in Milligrams — 5 MTD of oral LBH589 in milligrams
Phase 2 N=21 Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
Graft Versus Host Disease
Primary: GVHD-free Survival Rate — 33.3 percentage of patients
Phase 2 N=51 Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Hematologic Malignancies
Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects
Phase 2 N=29 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
Hematologic Malignancy
Primary: The Number of Patients With GVHD/Relapse-free (GRFS) Survival — 25 Participants
Phase 2 N=70 Itacitinib for Low Risk GVHD
Low Risk Acute Graft-versus-host Disease · Graft-versus-host-disease · GVHD
Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants
Phase 3 N=34 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Phase 3 N=136 Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
Graft Versus Host Disease (GVHD)
Primary: Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment — 60.0; 45.1 percentage of participants — p=0.034
Phase 1 N=13 Campath in Chronic GVHD
Chronic Graft-vs.-Host Disease
Primary: The Maximum Tolerated Dose (MTD) of a Four-week Course of Alemtuxumab in Chronic GVHD for Patients With an Incomplete Response to Steroids — 53 mg
Phase 2 N=81 Photopheresis for the Treatment of Acute Graft Versus Host Disease
Graft Versus Host Disease
Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants
Phase 3 N=151 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Chronic GVHD
Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63
Phase 2 N=122 A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Acute GVHD
Primary: Percentage of Participants With Complete or Partial Response (CR/PR) to Acute GVHD Treatment — 35; 46; 19; 17 Participants
Phase 2 N=40 A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
Graft vs Host Disease
Primary: Percentage of Patients That Respond to Treatment — 65 percentage of patients
Phase 2 N=49 RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
Graft Vs Host Disease · Graft-versus-host-disease · Acute-graft-versus-host Disease
Primary: Grades II-IV aGVHD — 11 Participants
Phase 2 N=65 Rituximab for Prevention of Chronic GVHD
Hematological Malignancies
Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants
Phase 3 N=439 GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Graft-versus-host Disease (GVHD)
Primary: Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index — 74.0; 66.4 Percentage of Participants — p=0.0782
Phase 2 N=379 A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplantation
Primary: Number of Subjects Not Experiencing Grade II-IV Acute Graph Versus Host Disease (aGVHD) — 3; 18; 0 Participants
Phase 1 N=9 Detection of Graft Versus Host Disease With [18F]F-AraG
Graft Versus Host Disease
Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants
Phase 3 N=55 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
Grade B aGVHD · Grade C aGVHD · Grade D aGVHD
Primary: Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy — 69.1 percentage of participants — p=0.0003
Phase 2 N=39 Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Leukemia · Lymphoma · Myelodysplastic Syndrome
Primary: Grade II-IV Acute GVHD — 30 percentage of participants
Phase 2 N=74 Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Acute Graft Versus Host Disease
Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants